The U.S. Food and Drug
Administration approved Akebia Therapeutics drug to
treat anemia caused by chronic kidney disease in dialysis
patients, the drugmaker said on Wednesday.
(Reporting by Pratik.
(Reuters) - The U.S. Food and Drug Administration approved Akebia Therapeutics' drug to treat anemia caused by chronic kidney disease in dialysis patients, the drugmaker said on Wednesday. (Reporting by Pratik Jain, Vaibhav Sadhamta and Mrinmay De.
Medtronic beat Wall Street
estimates for third-quarter profit on Tuesday, aided by strong
demand for its heart and diabetes devices. The company added that it decided to exit its.
Demand for medical devices has picked up pace as non-urgent procedures, which were deferred during the pandemic, recovered in the past year with easing hospital staff shortages and people becoming regular with check-ups. Medtronic expects adjusted profit for the fiscal 2024 to be between $5.19 and $5.21 per share, compared with its previous forecast range of $5.13 and $5.19 per share. Sales at the company's heart devices unit, its biggest revenue driver, increased 6.1% to $2.93 billion, versus analysts' estimate of $2.89 billion.
Centene Corp beat Wall Street
estimates for fourth-quarter profit on Tuesday, helped by higher
premiums in its commercial insurance business. The insurer also raise its forecast range.